Drug Profile
Afatinib - Boehringer Ingelheim
Alternative Names: Afatinib dimaleate; BIBW 2992 MA2; BIBW-2992; Gilotrif; Giotrif; Tomtovok; Tovok; XovoltibLatest Information Update: 05 Dec 2023
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Antineoplastics; Quinazolines; Radiation-sensitising agents; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
- Phase III Breast cancer; Head and neck cancer
- Phase II Chordoma; Glioma; HER2 negative breast cancer; Oesophageal cancer; Urogenital cancer
- Phase I/II Neuroectodermal tumours; Rhabdomyosarcoma
- No development reported Colorectal cancer; Gastric cancer; Glioblastoma; Pancreatic cancer; Prostate cancer; Solid tumours
Most Recent Events
- 22 Mar 2023 Boehringer Ingelheim completes phase II DARWIN1 trial for Non-small cell lung cancer in United Kingdom (NCT02183883)
- 20 Feb 2023 Memorial Sloan Kettering Cancer Center completes a phase II trial in Esophagogastric cancer in the USA (NCT01522768)
- 29 Nov 2022 No development reported - Phase-II for Gastric cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease) in Greece (PO)